SRF Limited approves revised capital expenditure of ₹2,285 crore for refrigerants project
SRF · Chemicals & Petrochemicals
Key highlights
- Original capital expenditure of ₹1,100 crore approved on October 22, 2024, revised to ₹2,285 crore on May 5, 2026
- Project includes 20,000 MTPA HFO plant, 30,000 MTPA AHF plant with forward integration into VHF products, and infrastructure development at Gopalpur, Odisha
- Completion expected by February 28, 2028, financed through debt and internal accruals
Why it's rated notable: amount is ₹500 crore or more
Original filing
Revision In Capital Expenditure
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from SRF
- Dividend / buyback / bonusMajor developmentSRF Limited announces Q1FY27 results with strong revenue and profit growth
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.